33 min
2022 ASH Annual Meeting: Highlights from the Perspective of a Conference Attendee Treating Blood Cancers
-
- Science
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY
Recorded on December 19, 2022
Lee Greenberger, PhD
Chief Scientific Officer and SVP
The Leukemia & Lymphoma Society
Rye Brook, NY
In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY
Recorded on December 19, 2022
Lee Greenberger, PhD
Chief Scientific Officer and SVP
The Leukemia & Lymphoma Society
Rye Brook, NY
In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!
33 min